Page 137 of 154: studies 1,361 to 1,370 of 1,534, newest first. Back to the ketamine for depression overview
The Brown University Child & Adolescent Psychopharmacology Update November 1, 2019
The recent approval of esketamine (Spravato) by the Food and Drug Administration (FDA) has raised many questions for psychiatrists who treat major depression, and even bigger questions for child psychiatrists. It's not approved for pediatric use by the FDA, but that doesn't mean it can't be prescribed off‐label.
Psychiatry Research November 1, 2019 Jun Dong, S. Min, H. Qiu et al. 26 citations
This study aimed to investigate the efficacy and safety of intermittent low-dose ketamine on improving the efficacy of ECT. Patients diagnosed with Major Depressive Disorder (MDD) (n = 134) were randomized into 3 groups: routine ECT group (group E, n = 45); repeated ketamine-assisted ECT group (group RK, n = 43), and intermittent ketamine-assisted ECT group (group IK, n = 46). Patients in group...
Alcoholism & Drug Abuse Weekly October 7, 2019 Alison Knopf
Like its predecessor intravenous ketamine, an anesthetic that has been used off‐label to treat depression, esketamine has shown great promise in treating a disease that can destroy quality of life and lead to suicide. The Food and Drug Administration (FDA) approved esketamine (Spravato) last spring for treating depression that is resistant to traditional treatments.
Journal of Addictions Nursing October 1, 2019 William J Lorman
Treatment resistant depression is a common and burdensome condition with poor outcomes and few treatment options. Approximately one third of patients with major depressive disorder are treatment resistant to the current antidepressants. In addition, depression in patients with bipolar disorder is typically poorly responsive to antidepressants. And so, there is an unmet need for rapidly acting...
Pharmaceuticals September 11, 2019 Brittany O’brien, Marijn Lijffijt, Allison Wells et al.
Childhood maltreatment is associated with a poor treatment response to conventional antidepressants and increased risk for treatment-resistant depression (TRD). The N-methyl-D-aspartate receptor (NDMAR) antagonist ketamine has been shown to rapidly improve symptoms of depression in patients with TRD. It is unknown if childhood maltreatment could influence ketamine’s treatment response. We...
The Brown University Psychopharmacology Update September 1, 2019
Esketamine nasal spray in combination with a newly initiated antidepressant was more effective than a new antidepressant plus placebo in reducing depressive symptoms in patients with treatment‐resistant depression, a Phase 3 study has found. Esketamine, the S‐enantiomer of ketamine, recently received Food and Drug Administration (FDA) approval for treatment‐resistant depression in adults. Study...
Carolina Digital Repository (University of North Carolina at Chapel Hill) August 16, 2019 Mary S. Garner
Background: Introduction: The average person has up to 15% lifetime risk for developing depression. Major depressive disorder symptoms can include a depressed mood, such as feeling sad or having more anger than normal, changes in appetite, loss of interest in activities or hobbies, psychomotor agitation or retardation, loss of energy, feelings of worthlessness or guilt, decreased ability to...
Behavioural Brain Research August 13, 2019 Andrew J. Polis, Paul J. Fitzgerald, Pho J. Hale et al. 58 citations
Discovering that the anesthetic drug ketamine has rapidly acting antidepressant effects in many individuals with major depression is one of the most important findings in clinical psychopharmacology in recent decades. The initial report of these effects in human subjects was based on a foundation of rodent preclinical studies carried out in the 1990s, and subsequent investigation has included...
BMJ Open August 1, 2019 Karen Lascelles, Lisa Marzano, Fiona Brand et al.
Objective It is recognised that ketamine treatment can reduce suicidal ideation (SI) in people with depression, at least in the short term. However, information is lacking on patients’ perspectives on such effects. Studying these can contribute to greater understanding of the mechanisms underlying impact of ketamine treatment on SI. The aim of this study was to investigate patients’ reports of...
International Immunopharmacology August 1, 2019 Daiyue Chang, Jinghua Zhao, Xintong Zhang et al.
Depression has become a common mental illness, and studies have shown that neuroinflammation is associated with depression. Ketamine is a rapid antidepressant. In order to obtain better antidepressant effects, it is necessary to explore the efficacy of combination therapy with ketamine and other antidepressants. DHA is an unsaturated fatty acid with excellent application prospects due to its...